Welcome to Rosetta Capital

We are a venture capital firm focused on the life science and medical device sectors.

Our mission is to invest in exceptional young companies that are able to deliver breakthrough medical advances.

Our investment strategy is focused primarily on direct secondary transactions, though we also make primary venture investments that complement our goals. As a secondary investor, we provide flexible liquidity solutions for other investors or corporations that wish to divest some or all of their investment assets or to access additional capital and resource to optimise investment outcomes. We bring new capital to the table to participate in follow-on financings and help support key programs through value-adding inflection points.

We are an experienced team that engages strategically with our portfolio company Boards, management teams and co-investors to help secure successful corporate partnerships, IPOs and trade sales.

Rosetta has raised five funds to date and is actively managing funds IV and V.

Donald Macpherson

Partner and Non-Executive Chairman

Donald Macpherson has more than 50 years’ experience in the financial services sector, and has been the chairman or non-executive director of many companies, including for example Fuller Smith & Turner, Homestyle, M&G Investment Trusts, MARS Asset Management and MITIE Group. He spent a large part of his career in what was to become the international investment banking arm of the NatWest Group, as Deputy Chairman of NatWest Markets and Chairman of NatWest Corporate Finance, which subsequently became Hawkpoint Partners.

Graham Fagg

Partner

Graham Fagg joined Rosetta in 2003. Graham has more than 35 years of experience in the pharma/biotech sectors, encompassing R&D, business development, strategic planning, and corporate and venture investing. He held senior positions at Ciba/Novartis and the Wellcome Trust, an investment role at Accel Partners, and was a partner at Seroba Life Sciences, where he was on the Boards of Ario Pharma, Quanta Fluid Solutions and Xention. Graham holds a PhD from University College London.

Graham has served Board roles or been responsible for portfolio companies including Akinion, Curalogic, Novagali, Painceptor, Paratek, Polyphor and Promimic. He is currently a director of Asarina and an observer of Destiny Pharma.

Michael Forer

Partner

Michael Forer was a co-founder of Rosetta in 2001. Michael has more than 20 years’ experience in the life science sector as an entrepreneur, advisor and investor, initially at Rothschild Asset Management. As a partner at Auven Therapeutics, he led the investment in Spirogen (sold to AstraZeneca) and the spin-out of ADC Therapeutics. Michael holds a BA in economics, a diploma in international business, and an LLB from the University of British Columbia before articling at the predecessor law firm of Norton Rose Canada.

Michael has held key Board roles in Rosetta portfolio companies including Aditech, KDev Investments, Resonant Medical and Rose Pharma.

Torsten Goesch

Partner

Torsten Goesch joined Rosetta in 2002. He combines a medical training with more than 25 years of operational and deal-making experience in the life science sector. Previously, he held senior operational roles at Biogen and Merck KGa. Torsten holds a MD PhD from the Heinrich Heine University in Dusseldorf and an MBA from the Kellogg School of Management in Chicago.

Torsten has played a key leadership role on the Boards of exited portfolio companies such as Cytochroma, Enobia and STI Technologies. He continues to serve on the Boards of Biosergen, Dilafor, EyeSense, Forward Pharma, Modus and ProMore, and to work with Merlion and Tepha.

Jonathan Hepple

Partner

Jon Hepple is a co-founder of Rosetta. He has more than 15 years’ investment experience in the life sciences industry. Previously, he was at Rothschild Asset Management and British Biotechnology Ltd. He was also a partner at Seroba Life Sciences, where he was on the Boards of Covagen and Opsona. Jon holds a PhD from Cambridge University.

Jon has held Board roles and is actively engaged in portfolio companies such as Catalyst Biosciences, GlycoMimetics, Novimmune, Procertus and Tranzyme, and also has worked closely with GeminX, Polyphor and Zealand. He currently serves on the Boards of Aprea and Clanotech.

Sarah Laidler

Director of Finance and Compliance

Sarah Laidler joined Rosetta in 2016, bringing with her considerable experience from other senior finance roles in FCA regulated entities. Sarah is a Chartered Accountant and has worked with large corporates such as Phoenix Group and Swiss Re, as well as taking on the Finance Director role in smaller entities such as the private equity owned Learning World.

Sarah qualified with KPMG in 1999 and she is a member of the ICAEW. She has a BSc honours degree in Accounting and Financial Analysis from the University of Warwick and is authorised by the Financial Conduct Authority to lead the Compliance Oversight and Money Laundering Reporting functions within Rosetta.

Rosetta is headquartered in the UK and our team is located across Europe and Asia, providing us with broad geographic networks that have proven useful to support our portfolio companies.

Our team is supported by some outstanding international firms that we have worked with for a number of years, providing fund administration, audit, compliance, legal and accounting services.

Rosetta invests in companies that have the potential to transform medical care.

Our focus is on companies at late-preclinical or clinical stages of development that are developing innovative therapeutics, medical devices or diagnostics.

We manage a series of venture funds, primarily with a secondary investment focus, and currently are actively managing our funds IV and V. Our portfolio companies are located across Europe, North America and Asia.

A selection of our portfolio of companies is shown below.

All
EXITED INVESTMENTS
PRIVATE COMPANIES
PUBLICLY-LISTED COMPANIES

AEGERA

Cancer therapeutics
Acquired by Pharmascience

AMBIT

Cancer therapeutics
Acquired by Daiichi Sankyo

CURALOGIC

Immune therapeutics
Public: NASDAQ OMX

CYTOCHROMA

Renal disease therapeutics
Acquired by OPKO Health

ENOBIA

Orphan diseases
Acquired by Alexion

GEMINX

Cancer therapeutics
Acquired by Cephalon

RESONANT

Cancer imaging
Acquired by Elekta

ROSE PHARMA

GI therapeutics

STI

Health outcomes support
Trade sale

TEPHA

Surgical biomaterials

TOPIGEN

Respiratory therapeutics
Acquired by Pharmaxis

Rosetta Capital Limited
Nexus Building
Suite 301
Broadway
Letchworth Garden City
Hertfordshire
SG6 3TA
United Kingdom
Tel: +44 (0) 1462 686 644
Email: info@rosettacapital.com

Rosetta Capital Limited
Rectory House
Thame Road
Haddenham
Aylesbury
Buckinghamshire
HP17 8DA
United Kingdom
Tel: +44 (0) 1844 291 444
Email: info@rosettacapital.com